Drug Metabolizing Enzyme

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 282 Experts worldwide ranked by ideXlab platform

Penkhae Limsila - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.
    Frontiers in Pharmacology, 2016
    Co-Authors: Sadeep Medhasi, Darawan Pinthong, Ekawat Pasomsub, Natchaya Vanwong, Nattawat Ngamsamut, Apichaya Puangpetch, Monpat Chamnanphon, Yaowaluck Hongkaew, Jirawat Pratoomwun, Penkhae Limsila
    Abstract:

    The present study sought to investigate the genetic variants in Drug Metabolizing Enzyme and transporter (DMET) genes associated with steady-state plasma concentrations of risperidone among Thai autism spectrum disorder (ASD) patients. ASD patients taking risperidone for at least one month were enrolled for this pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay. The final analysis included 483 markers for 167 genes. Six variants, ABCB11 (c.3084A>G, c.*420A>G, c.*368G>A, and c.*236G>A) and ADH7 (c.690G>A and c.-5360G>A), were found to be associated with plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety levels were associated with six gene variants, SCLO1B1 (c.-11187G>A and c.521T>C), SLCO1B3 (c.334G>T, c.699A>G, and c.1557G>A), and SLC7A5 c.*438C>G. Polymorphisms in UGT2B4 c.*448A>G and CYP2D6 (c.1661G>C, c.4180G>C, and c.-2178G>A) showed considerable but not significant associations with metabolic ratio. This pharmacogenomic study identifies new genetic variants of DMET genes in monitoring risperidone therapy.

  • Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.
    Frontiers in pharmacology, 2016
    Co-Authors: Sadeep Medhasi, Darawan Pinthong, Ekawat Pasomsub, Natchaya Vanwong, Nattawat Ngamsamut, Apichaya Puangpetch, Monpat Chamnanphon, Yaowaluck Hongkaew, Jirawat Pratoomwun, Penkhae Limsila
    Abstract:

    The present study sought to investigate the genetic variants in Drug Metabolizing Enzyme and transporter (DMET) genes associated with steady-state plasma concentrations of risperidone among Thai autism spectrum disorder (ASD) patients. ASD patients taking risperidone for at least one month were enrolled for this pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay. The final analysis included 483 markers for 167 genes. Six variants, ABCB11 (c.3084A>G, c.*420A>G, c.*368G>A, and c.*236G>A) and ADH7 (c.690G>A and c.-5360G>A), were found to be associated with plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety levels were associated with six gene variants, SCLO1B1 (c.-11187G>A and c.521T>C), SLCO1B3 (c.334G>T, c.699A>G, and c.1557G>A), and SLC7A5 c.*438C>G. Polymorphisms in UGT2B4 c.*448A>G and CYP2D6 (c.1661G>C, c.4180G>C, and c.-2178G>A) showed considerable but not significant associations with metabolic ratio. This pharmacogenomic study identifies new genetic variants of DMET genes in monitoring risperidone therapy.

Sadeep Medhasi - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.
    Frontiers in Pharmacology, 2016
    Co-Authors: Sadeep Medhasi, Darawan Pinthong, Ekawat Pasomsub, Natchaya Vanwong, Nattawat Ngamsamut, Apichaya Puangpetch, Monpat Chamnanphon, Yaowaluck Hongkaew, Jirawat Pratoomwun, Penkhae Limsila
    Abstract:

    The present study sought to investigate the genetic variants in Drug Metabolizing Enzyme and transporter (DMET) genes associated with steady-state plasma concentrations of risperidone among Thai autism spectrum disorder (ASD) patients. ASD patients taking risperidone for at least one month were enrolled for this pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay. The final analysis included 483 markers for 167 genes. Six variants, ABCB11 (c.3084A>G, c.*420A>G, c.*368G>A, and c.*236G>A) and ADH7 (c.690G>A and c.-5360G>A), were found to be associated with plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety levels were associated with six gene variants, SCLO1B1 (c.-11187G>A and c.521T>C), SLCO1B3 (c.334G>T, c.699A>G, and c.1557G>A), and SLC7A5 c.*438C>G. Polymorphisms in UGT2B4 c.*448A>G and CYP2D6 (c.1661G>C, c.4180G>C, and c.-2178G>A) showed considerable but not significant associations with metabolic ratio. This pharmacogenomic study identifies new genetic variants of DMET genes in monitoring risperidone therapy.

  • Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.
    Frontiers in pharmacology, 2016
    Co-Authors: Sadeep Medhasi, Darawan Pinthong, Ekawat Pasomsub, Natchaya Vanwong, Nattawat Ngamsamut, Apichaya Puangpetch, Monpat Chamnanphon, Yaowaluck Hongkaew, Jirawat Pratoomwun, Penkhae Limsila
    Abstract:

    The present study sought to investigate the genetic variants in Drug Metabolizing Enzyme and transporter (DMET) genes associated with steady-state plasma concentrations of risperidone among Thai autism spectrum disorder (ASD) patients. ASD patients taking risperidone for at least one month were enrolled for this pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay. The final analysis included 483 markers for 167 genes. Six variants, ABCB11 (c.3084A>G, c.*420A>G, c.*368G>A, and c.*236G>A) and ADH7 (c.690G>A and c.-5360G>A), were found to be associated with plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety levels were associated with six gene variants, SCLO1B1 (c.-11187G>A and c.521T>C), SLCO1B3 (c.334G>T, c.699A>G, and c.1557G>A), and SLC7A5 c.*438C>G. Polymorphisms in UGT2B4 c.*448A>G and CYP2D6 (c.1661G>C, c.4180G>C, and c.-2178G>A) showed considerable but not significant associations with metabolic ratio. This pharmacogenomic study identifies new genetic variants of DMET genes in monitoring risperidone therapy.

Natchaya Vanwong - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.
    Frontiers in Pharmacology, 2016
    Co-Authors: Sadeep Medhasi, Darawan Pinthong, Ekawat Pasomsub, Natchaya Vanwong, Nattawat Ngamsamut, Apichaya Puangpetch, Monpat Chamnanphon, Yaowaluck Hongkaew, Jirawat Pratoomwun, Penkhae Limsila
    Abstract:

    The present study sought to investigate the genetic variants in Drug Metabolizing Enzyme and transporter (DMET) genes associated with steady-state plasma concentrations of risperidone among Thai autism spectrum disorder (ASD) patients. ASD patients taking risperidone for at least one month were enrolled for this pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay. The final analysis included 483 markers for 167 genes. Six variants, ABCB11 (c.3084A>G, c.*420A>G, c.*368G>A, and c.*236G>A) and ADH7 (c.690G>A and c.-5360G>A), were found to be associated with plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety levels were associated with six gene variants, SCLO1B1 (c.-11187G>A and c.521T>C), SLCO1B3 (c.334G>T, c.699A>G, and c.1557G>A), and SLC7A5 c.*438C>G. Polymorphisms in UGT2B4 c.*448A>G and CYP2D6 (c.1661G>C, c.4180G>C, and c.-2178G>A) showed considerable but not significant associations with metabolic ratio. This pharmacogenomic study identifies new genetic variants of DMET genes in monitoring risperidone therapy.

  • Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.
    Frontiers in pharmacology, 2016
    Co-Authors: Sadeep Medhasi, Darawan Pinthong, Ekawat Pasomsub, Natchaya Vanwong, Nattawat Ngamsamut, Apichaya Puangpetch, Monpat Chamnanphon, Yaowaluck Hongkaew, Jirawat Pratoomwun, Penkhae Limsila
    Abstract:

    The present study sought to investigate the genetic variants in Drug Metabolizing Enzyme and transporter (DMET) genes associated with steady-state plasma concentrations of risperidone among Thai autism spectrum disorder (ASD) patients. ASD patients taking risperidone for at least one month were enrolled for this pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay. The final analysis included 483 markers for 167 genes. Six variants, ABCB11 (c.3084A>G, c.*420A>G, c.*368G>A, and c.*236G>A) and ADH7 (c.690G>A and c.-5360G>A), were found to be associated with plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety levels were associated with six gene variants, SCLO1B1 (c.-11187G>A and c.521T>C), SLCO1B3 (c.334G>T, c.699A>G, and c.1557G>A), and SLC7A5 c.*438C>G. Polymorphisms in UGT2B4 c.*448A>G and CYP2D6 (c.1661G>C, c.4180G>C, and c.-2178G>A) showed considerable but not significant associations with metabolic ratio. This pharmacogenomic study identifies new genetic variants of DMET genes in monitoring risperidone therapy.

Darawan Pinthong - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.
    Frontiers in Pharmacology, 2016
    Co-Authors: Sadeep Medhasi, Darawan Pinthong, Ekawat Pasomsub, Natchaya Vanwong, Nattawat Ngamsamut, Apichaya Puangpetch, Monpat Chamnanphon, Yaowaluck Hongkaew, Jirawat Pratoomwun, Penkhae Limsila
    Abstract:

    The present study sought to investigate the genetic variants in Drug Metabolizing Enzyme and transporter (DMET) genes associated with steady-state plasma concentrations of risperidone among Thai autism spectrum disorder (ASD) patients. ASD patients taking risperidone for at least one month were enrolled for this pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay. The final analysis included 483 markers for 167 genes. Six variants, ABCB11 (c.3084A>G, c.*420A>G, c.*368G>A, and c.*236G>A) and ADH7 (c.690G>A and c.-5360G>A), were found to be associated with plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety levels were associated with six gene variants, SCLO1B1 (c.-11187G>A and c.521T>C), SLCO1B3 (c.334G>T, c.699A>G, and c.1557G>A), and SLC7A5 c.*438C>G. Polymorphisms in UGT2B4 c.*448A>G and CYP2D6 (c.1661G>C, c.4180G>C, and c.-2178G>A) showed considerable but not significant associations with metabolic ratio. This pharmacogenomic study identifies new genetic variants of DMET genes in monitoring risperidone therapy.

  • Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.
    Frontiers in pharmacology, 2016
    Co-Authors: Sadeep Medhasi, Darawan Pinthong, Ekawat Pasomsub, Natchaya Vanwong, Nattawat Ngamsamut, Apichaya Puangpetch, Monpat Chamnanphon, Yaowaluck Hongkaew, Jirawat Pratoomwun, Penkhae Limsila
    Abstract:

    The present study sought to investigate the genetic variants in Drug Metabolizing Enzyme and transporter (DMET) genes associated with steady-state plasma concentrations of risperidone among Thai autism spectrum disorder (ASD) patients. ASD patients taking risperidone for at least one month were enrolled for this pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay. The final analysis included 483 markers for 167 genes. Six variants, ABCB11 (c.3084A>G, c.*420A>G, c.*368G>A, and c.*236G>A) and ADH7 (c.690G>A and c.-5360G>A), were found to be associated with plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety levels were associated with six gene variants, SCLO1B1 (c.-11187G>A and c.521T>C), SLCO1B3 (c.334G>T, c.699A>G, and c.1557G>A), and SLC7A5 c.*438C>G. Polymorphisms in UGT2B4 c.*448A>G and CYP2D6 (c.1661G>C, c.4180G>C, and c.-2178G>A) showed considerable but not significant associations with metabolic ratio. This pharmacogenomic study identifies new genetic variants of DMET genes in monitoring risperidone therapy.

Nattawat Ngamsamut - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.
    Frontiers in Pharmacology, 2016
    Co-Authors: Sadeep Medhasi, Darawan Pinthong, Ekawat Pasomsub, Natchaya Vanwong, Nattawat Ngamsamut, Apichaya Puangpetch, Monpat Chamnanphon, Yaowaluck Hongkaew, Jirawat Pratoomwun, Penkhae Limsila
    Abstract:

    The present study sought to investigate the genetic variants in Drug Metabolizing Enzyme and transporter (DMET) genes associated with steady-state plasma concentrations of risperidone among Thai autism spectrum disorder (ASD) patients. ASD patients taking risperidone for at least one month were enrolled for this pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay. The final analysis included 483 markers for 167 genes. Six variants, ABCB11 (c.3084A>G, c.*420A>G, c.*368G>A, and c.*236G>A) and ADH7 (c.690G>A and c.-5360G>A), were found to be associated with plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety levels were associated with six gene variants, SCLO1B1 (c.-11187G>A and c.521T>C), SLCO1B3 (c.334G>T, c.699A>G, and c.1557G>A), and SLC7A5 c.*438C>G. Polymorphisms in UGT2B4 c.*448A>G and CYP2D6 (c.1661G>C, c.4180G>C, and c.-2178G>A) showed considerable but not significant associations with metabolic ratio. This pharmacogenomic study identifies new genetic variants of DMET genes in monitoring risperidone therapy.

  • Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.
    Frontiers in pharmacology, 2016
    Co-Authors: Sadeep Medhasi, Darawan Pinthong, Ekawat Pasomsub, Natchaya Vanwong, Nattawat Ngamsamut, Apichaya Puangpetch, Monpat Chamnanphon, Yaowaluck Hongkaew, Jirawat Pratoomwun, Penkhae Limsila
    Abstract:

    The present study sought to investigate the genetic variants in Drug Metabolizing Enzyme and transporter (DMET) genes associated with steady-state plasma concentrations of risperidone among Thai autism spectrum disorder (ASD) patients. ASD patients taking risperidone for at least one month were enrolled for this pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay. The final analysis included 483 markers for 167 genes. Six variants, ABCB11 (c.3084A>G, c.*420A>G, c.*368G>A, and c.*236G>A) and ADH7 (c.690G>A and c.-5360G>A), were found to be associated with plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety levels were associated with six gene variants, SCLO1B1 (c.-11187G>A and c.521T>C), SLCO1B3 (c.334G>T, c.699A>G, and c.1557G>A), and SLC7A5 c.*438C>G. Polymorphisms in UGT2B4 c.*448A>G and CYP2D6 (c.1661G>C, c.4180G>C, and c.-2178G>A) showed considerable but not significant associations with metabolic ratio. This pharmacogenomic study identifies new genetic variants of DMET genes in monitoring risperidone therapy.

Drug Metabolizing Enzyme - 15 days free trial to Access Experts & Abstracts